Targeted agent addition to herceptin has positive effect on metastatic HER-2 breast cancer
Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a study led by researchers ...
Jul 8, 2011
0
0